Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
Frontiers in Oncology · 22.10.2025 · 15
DOI: 10.3389/fonc.2025.1587752 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 22.10.2025. Verfasst von Ellen Reusch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Markey Cancer Center, University of Kentucky, Lexington, KY, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Meningiomas are the most common primary tumor in the central nervous system, yet an effective systemic treatment remains a challenge. We present a grade 2 meningioma that resulted in a positive and prolonged response to pembrolizumab. Our case had polybromo-1 ( PBRM1 ) and BAP1 functional loss, tumor mutational burden of 4 Muts/Mb, stable microsatellite status, and a PD-L1 tumor proportion score of <1%. We add to the limited literature regarding PBRM1 mutations in meningiomas. We discuss our findings in relation to the ongoing investigation of immune checkpoint inhibitor therapy in treating higher-grade refractory meningiomas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
- College of Pharmacy, University of Kentucky, Lexington, KY, United States.
- College of Medicine, University of Kentucky, Lexington, KY, United States.
- Molecular Science Liaison Group, Caris Life Sciences, Phoenix, AZ, United States.
- Department of Neurosurgery, University of Kentucky, Lexington, KY, United States.
- Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States.
Förderung
- National Institutes of Health
Zitieren
APA
Reusch, E., Peh, K. H., Morgan, R., Momo, H., Orren, D., Rock, S., Pittman, T., Neltner, J., Kolesar, J., & Villano, J. (2025). Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1587752
Vancouver
Reusch E, Peh KH, Morgan R, Momo H, Orren D, Rock S, et al. Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1587752
BibTeX
@article{Reusch2025,
author = {Reusch, Ellen and Peh, Keng Hee and Morgan, Rachael and Momo, Harry and Orren, David and Rock, Stephanie and Pittman, Thomas and Neltner, Janna and Kolesar, Jill and Villano, John},
title = {Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1587752}
}
EUVIMED